isoniazid has been researched along with Disease Exacerbation in 37 studies
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the efficacy of isoniazid 300 mg daily for 6 months in the prevention of tuberculosis in HIV-1-infected adults and to determine whether tuberculosis preventive therapy prolongs survival in HIV-1-infected adults." | 9.08 | Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. ( Bwayo, JJ; Chakaya, JM; Elliott, LC; Gilks, CF; Githui, WA; Hawken, MP; Juma, ES; Kimari, JN; McAdam, KP; Meme, HK; Morris, JS; Ngugi, EN; Nunn, PP; Odhiambo, JA; Plummer, FA; Porter, JD; Thiong'o, LN, 1997) |
| "We report treatment outcomes from a retrospective cohort of patients with isoniazid-monoresistant tuberculosis in rural South Africa." | 7.77 | Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. ( Jacobson, KR; Murray, MB; Streicher, EM; Theron, D; Victor, TC; Warren, RM, 2011) |
| "Antiretroviral therapy and isoniazid preventive therapy (IPT) are both effective interventions to prevent HIV-associated tuberculosis, but work via different mechanisms." | 7.76 | Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. ( Churchyard, GJ; De Cock, KM; Kranzer, K; Lawn, SD; Lewis, JJ; Wood, R, 2010) |
| "To determine the efficacy of isoniazid 300 mg daily for 6 months in the prevention of tuberculosis in HIV-1-infected adults and to determine whether tuberculosis preventive therapy prolongs survival in HIV-1-infected adults." | 5.08 | Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. ( Bwayo, JJ; Chakaya, JM; Elliott, LC; Gilks, CF; Githui, WA; Hawken, MP; Juma, ES; Kimari, JN; McAdam, KP; Meme, HK; Morris, JS; Ngugi, EN; Nunn, PP; Odhiambo, JA; Plummer, FA; Porter, JD; Thiong'o, LN, 1997) |
| "We report treatment outcomes from a retrospective cohort of patients with isoniazid-monoresistant tuberculosis in rural South Africa." | 3.77 | Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. ( Jacobson, KR; Murray, MB; Streicher, EM; Theron, D; Victor, TC; Warren, RM, 2011) |
| "Antiretroviral therapy and isoniazid preventive therapy (IPT) are both effective interventions to prevent HIV-associated tuberculosis, but work via different mechanisms." | 3.76 | Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. ( Churchyard, GJ; De Cock, KM; Kranzer, K; Lawn, SD; Lewis, JJ; Wood, R, 2010) |
| "The standard antitubercular treatment (ATT), which consists of isoniazid (INH), rifampicin (RIF), ethambutol, and pyrazinamide (PZA), is the best available treatment for tuberculosis (TB)." | 3.76 | Acute liver failure due to antitubercular therapy: Strategy for antitubercular treatment before and after liver transplantation. ( Antonini, TM; Antoun, F; Azoulay, D; Castaing, D; Delvart, V; Escaut, L; Ichai, P; Saliba, F; Samuel, D; Sebagh, M, 2010) |
| "To evaluate tuberculosis (TB) prevention in HIV clinics based on the prevalence and incidence of TB and the efficacy of preventive therapy with isoniazid (INH)." | 3.71 | TB prevention in HIV clinics in New York City. ( Frieden, TR; Sackoff, JE; Torian, LV, 2001) |
| " We studied the effect of INH on LPV concentrations by administering INH for 7 days and performing intensive pharmacokinetic sampling in 16 human immunodeficiency virus infected patients established on LPV/r-based ART." | 2.80 | The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals. ( Decloedt, EH; Maartens, G; McIlleron, H; van der Walt, JS; Wiesner, L, 2015) |
| "Tuberculosis was associated with an increased mortality (adjusted rate ratio 1." | 2.70 | Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. ( Fuchs, D; Godfrey-Faussett, P; Hosp, M; Lisse, I; Mwinga, A; Quigley, MA, 2001) |
| " Stochastic PK/pharmacodynamic (PD) simulations were carried out to evaluate current regimen combinations and dosing guidelines in distinct patient strata." | 1.51 | Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization. ( Bang, H; Barry, CE; Dartois, V; Eum, S; Fox, WS; Gupta, SV; Lee, M; Savic, RM; Shim, T; Strydom, N; Via, LE; Zimmerman, M, 2019) |
| "Suspected latent tuberculosis infection (LTBI) is a common reason for referral to TB clinics." | 1.39 | Does an interferon-gamma release assay change practice in possible latent tuberculosis? ( Chalmers, JD; Gilhooley, S; Hill, AT; Jones, ME; Laurenson, IF; McSparron, C; Tiernan, JF, 2013) |
| "When active tuberculosis is identified, combination therapy with isoniazid, rifampin, pyrazinamide, and ethambutol should be promptly initiated for a two-month "intensive phase," and in most cases, followed by isoniazid and a rifamycin product for a four- to seven-month "continuation phase." | 1.35 | Update on the treatment of tuberculosis. ( Inge, LD; Wilson, JW, 2008) |
| "No other case of spondylodiscitis caused by a mycobacterial coinfection pathogen has been reported so far." | 1.33 | [Cervical spondylodiscitis: one pathogen may hide another]. ( Ader, F; Bernard, L; Carlier, R; Perronne, C; Salomon, J; Toubiana, J, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (10.81) | 18.2507 |
| 2000's | 16 (43.24) | 29.6817 |
| 2010's | 17 (45.95) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Becerra, MC | 1 |
| Huang, CC | 1 |
| Lecca, L | 1 |
| Bayona, J | 1 |
| Contreras, C | 1 |
| Calderon, R | 1 |
| Yataco, R | 1 |
| Galea, J | 1 |
| Zhang, Z | 1 |
| Atwood, S | 1 |
| Cohen, T | 1 |
| Mitnick, CD | 1 |
| Farmer, P | 1 |
| Murray, M | 1 |
| Soto-Cabrera, E | 1 |
| Villamil-Osorio, LV | 1 |
| Garcia-Luna, RC | 1 |
| Carrera-Pineda, R | 1 |
| Meremikwu, M | 1 |
| Zumla, A | 1 |
| Strydom, N | 1 |
| Gupta, SV | 1 |
| Fox, WS | 1 |
| Via, LE | 1 |
| Bang, H | 1 |
| Lee, M | 1 |
| Eum, S | 1 |
| Shim, T | 1 |
| Barry, CE | 1 |
| Zimmerman, M | 1 |
| Dartois, V | 1 |
| Savic, RM | 1 |
| Vernon, A | 1 |
| Boerrigter, BG | 1 |
| van Sandwijk, MS | 1 |
| van den Berk, GE | 1 |
| Lin, PL | 1 |
| Ford, CB | 1 |
| Coleman, MT | 1 |
| Myers, AJ | 1 |
| Gawande, R | 1 |
| Ioerger, T | 1 |
| Sacchettini, J | 1 |
| Fortune, SM | 1 |
| Flynn, JL | 1 |
| Matei, L | 1 |
| Bleotu, C | 1 |
| Baciu, I | 1 |
| Diaconu, CC | 1 |
| Hanganu, A | 1 |
| Banu, O | 1 |
| Ionita, P | 1 |
| Paun, A | 1 |
| Tatibouët, A | 1 |
| Zarafu, I | 1 |
| Wasserman, S | 1 |
| Meintjes, G | 1 |
| Decloedt, EH | 1 |
| van der Walt, JS | 1 |
| McIlleron, H | 1 |
| Wiesner, L | 1 |
| Maartens, G | 1 |
| Silva, AP | 1 |
| Hill, P | 1 |
| Belo, MT | 1 |
| Rabelo, SG | 1 |
| Menzies, D | 1 |
| Trajman, A | 1 |
| Zhuo, C | 1 |
| Li, X | 1 |
| Zhuang, H | 1 |
| Tian, S | 1 |
| Cui, H | 1 |
| Jiang, R | 1 |
| Liu, C | 1 |
| Tao, R | 1 |
| Lin, X | 1 |
| Padmavathy, L | 1 |
| Rao, LL | 1 |
| Ethirajan, N | 1 |
| Dhanlaklshmi, M | 1 |
| Inge, LD | 1 |
| Wilson, JW | 1 |
| Pelfort, X | 1 |
| Horcajada, JP | 1 |
| Puig, L | 1 |
| Salvadó, M | 1 |
| Skvortsova, LA | 1 |
| Pavlova, MV | 1 |
| Kondakova, MN | 1 |
| Vinogradova, TI | 1 |
| Kovaleva, RG | 1 |
| Archakova, LI | 1 |
| Lawn, SD | 1 |
| Wood, R | 1 |
| De Cock, KM | 1 |
| Kranzer, K | 1 |
| Lewis, JJ | 1 |
| Churchyard, GJ | 1 |
| Ichai, P | 1 |
| Saliba, F | 1 |
| Antoun, F | 1 |
| Azoulay, D | 1 |
| Sebagh, M | 1 |
| Antonini, TM | 1 |
| Escaut, L | 1 |
| Delvart, V | 1 |
| Castaing, D | 1 |
| Samuel, D | 1 |
| Jacobson, KR | 1 |
| Theron, D | 1 |
| Victor, TC | 1 |
| Streicher, EM | 1 |
| Warren, RM | 1 |
| Murray, MB | 1 |
| Duarte, R | 1 |
| Carvalho, A | 1 |
| Correia, A | 1 |
| Tiernan, JF | 1 |
| Gilhooley, S | 1 |
| Jones, ME | 1 |
| Chalmers, JD | 1 |
| McSparron, C | 1 |
| Laurenson, IF | 1 |
| Hill, AT | 1 |
| Chelnokova, OG | 2 |
| Kibrik, BS | 2 |
| Long, R | 1 |
| Bochar, K | 1 |
| Chomyc, S | 1 |
| Talbot, J | 1 |
| Barrie, J | 1 |
| Kunimoto, D | 1 |
| Tilley, P | 1 |
| Frisch, IB | 1 |
| Kunze, AK | 1 |
| Castro, A | 1 |
| Krastel, H | 1 |
| Meinck, HM | 1 |
| Chacko, AG | 1 |
| Moorthy, RK | 1 |
| Chandy, MJ | 1 |
| Rabar, D | 1 |
| Issartel, B | 1 |
| Petiot, P | 1 |
| Boibieux, A | 1 |
| Chidiac, C | 1 |
| Peyramond, D | 1 |
| Toubiana, J | 1 |
| Salomon, J | 1 |
| Ader, F | 1 |
| Perronne, C | 1 |
| Carlier, R | 1 |
| Bernard, L | 1 |
| Schechter, M | 1 |
| Zajdenverg, R | 1 |
| Falco, G | 1 |
| Barnes, GL | 1 |
| Faulhaber, JC | 1 |
| Coberly, JS | 1 |
| Moore, RD | 1 |
| Chaisson, RE | 1 |
| Hawken, MP | 1 |
| Meme, HK | 1 |
| Elliott, LC | 1 |
| Chakaya, JM | 1 |
| Morris, JS | 1 |
| Githui, WA | 1 |
| Juma, ES | 1 |
| Odhiambo, JA | 1 |
| Thiong'o, LN | 1 |
| Kimari, JN | 1 |
| Ngugi, EN | 1 |
| Bwayo, JJ | 1 |
| Gilks, CF | 1 |
| Plummer, FA | 1 |
| Porter, JD | 1 |
| Nunn, PP | 1 |
| McAdam, KP | 1 |
| Brik, R | 1 |
| Magen, D | 1 |
| Ben-Yzhak, O | 1 |
| Grin, J | 1 |
| Takamatsu, I | 1 |
| Asano, T | 1 |
| Kawamoto, H | 1 |
| Asakuma, J | 1 |
| Tanimoto, T | 1 |
| Kobayashi, H | 1 |
| Hayakawa, M | 1 |
| Quigley, MA | 1 |
| Mwinga, A | 1 |
| Hosp, M | 1 |
| Lisse, I | 1 |
| Fuchs, D | 1 |
| Godfrey-Faussett, P | 1 |
| Sackoff, JE | 1 |
| Torian, LV | 1 |
| Frieden, TR | 1 |
| Grange, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Epidemiology of Multidrug-Resistant Tuberculosis in Peru[NCT00676754] | 18,544 participants (Actual) | Observational | 2009-09-30 | Active, not recruiting | |||
| Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery[NCT00816426] | Phase 1 | 19 participants (Actual) | Interventional | 2008-12-29 | Completed | ||
| Evaluation of Two Different Preventive Therapy Regimens for Tuberculosis in HIV Infected Persons[NCT00351702] | Phase 3 | 650 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for isoniazid and Disease Exacerbation
| Article | Year |
|---|---|
Treatment of latent tuberculosis infection.
Topics: Antitubercular Agents; Disease Progression; Drug Resistance, Bacterial; Drug Therapy, Combination; H | 2013 |
The diagnosis, management and prevention of HIV-associated tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; Disease Progre | 2014 |
Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocol | 2016 |
[Factors for the onset of and the exacerbation of tuberculosis. 3. Clinical factors for the development and the exacerbation of active tuberculosis. a. Children, young adult].
Topics: Adolescent; Adult; Age Factors; Antitubercular Agents; BCG Vaccine; Child; Child, Preschool; Disease | 1999 |
5 trials available for isoniazid and Disease Exacerbation
| Article | Year |
|---|---|
Transmissibility and potential for disease progression of drug resistant
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Contact Tracing; Disease Pr | 2019 |
The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Biological Availability; Disease Pr | 2015 |
Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
Topics: Adult; Antitubercular Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combi | 2006 |
Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Disease Progr | 1997 |
Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Cohort St | 2001 |
28 other studies available for isoniazid and Disease Exacerbation
| Article | Year |
|---|---|
[Optochiasmatic tuberculomas as a paradoxical reaction to treatment for meningeal tuberculosis].
Topics: Adult; Antitubercular Agents; Brain Infarction; Diagnostic Errors; Disease Progression; Drug Resista | 2018 |
Isoniazid preventive therapy for children in sub-Saharan Africa.
Topics: Africa South of the Sahara; Antitubercular Agents; Chemoprevention; Child; Disease Progression; HIV | 2019 |
Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization.
Topics: Adult; Antitubercular Agents; Decision Support Techniques; Disease Progression; Drug Administration | 2019 |
A breathtaking response to tuberculosis therapy.
Topics: Adult; Antitubercular Agents; Disease Progression; Dyspnea; Ethambutol; Female; Humans; Isoniazid; M | 2013 |
Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing.
Topics: Adaptive Immunity; Animals; Disease Progression; Granuloma; Isoniazid; Latent Tuberculosis; Lung; Ma | 2014 |
Synthesis and biological activities of some new isonicotinic acid 2-(2-hydroxy-8-substituted-tricyclo[7.3.1.0(2.7)]tridec-13-ylidene)-hydrazides.
Topics: Anti-Bacterial Agents; Antioxidants; Antitubercular Agents; Disease Progression; HT29 Cells; Humans; | 2015 |
Non-completion of latent tuberculous infection treatment among children in Rio de Janeiro State, Brazil.
Topics: Antitubercular Agents; Brazil; Child; Disease Progression; Female; Follow-Up Studies; Humans; Incide | 2016 |
Psoriasiform lupus vulgaris.
Topics: Adolescent; Antitubercular Agents; Biopsy; Buttocks; Child; Disease Progression; Ethambutol; Female; | 2008 |
Update on the treatment of tuberculosis.
Topics: Antitubercular Agents; Comorbidity; Directly Observed Therapy; Disease Progression; Drug Therapy, Co | 2008 |
[Pain, swelling, and progressive weakness of the left knee over 6 years].
Topics: Accidents, Traffic; Antitubercular Agents; Arthritis, Infectious; Disease Progression; Ethambutol; H | 2008 |
[A role of the HLA-DRB1* genotype in the complex therapy of pulmonary tuberculosis].
Topics: Alleles; Antibiotics, Antitubercular; Antitubercular Agents; Disease Progression; Drug Resistance, B | 2008 |
Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources.
Topics: Anti-Retroviral Agents; CD4 Lymphocyte Count; Disease Progression; HIV Infections; Humans; Isoniazid | 2010 |
Acute liver failure due to antitubercular therapy: Strategy for antitubercular treatment before and after liver transplantation.
Topics: Adolescent; Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Disease Progressio | 2010 |
Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa.
Topics: Adult; Aged; Antitubercular Agents; Bacterial Proteins; Catalase; Cohort Studies; Disease Progressio | 2011 |
Two-month regimen of isoniazid, rifampin and pirazinamid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Cohort Studies; Disease Progression; Drug Therapy, Combination; Female | 2012 |
Does an interferon-gamma release assay change practice in possible latent tuberculosis?
Topics: Adult; Antitubercular Agents; Disease Progression; Drug Therapy, Combination; Female; Humans; Interf | 2013 |
[Use of isofon in combined treatment of patients with acutely progressive forms of tuberculosis].
Topics: Acute Disease; Adjuvants, Immunologic; Antitubercular Agents; Arrhythmias, Cardiac; Disease Progress | 2003 |
Relative versus absolute noncontagiousness of respiratory tuberculosis on treatment.
Topics: Academic Medical Centers; Adult; Alberta; Antibiotics, Antitubercular; Antitubercular Agents; Colony | 2003 |
[Severe course and contingent risk factors in optic neuropathy and myelopathy after tuberculostatics].
Topics: Adult; Antitubercular Agents; Disease Progression; Drug Therapy, Combination; Ethambutol; Humans; Is | 2003 |
The transpedicular approach in the management of thoracic spine tuberculosis: a short-term follow up study.
Topics: Abscess; Adolescent; Adult; Aged; Antitubercular Agents; Braces; Combined Modality Therapy; Curettag | 2004 |
[Tuberculoma and tuberculous meningeal-radiculitis with paradoxical progression during treatment].
Topics: Aged; Anti-Inflammatory Agents; Antitubercular Agents; Confusion; Disease Progression; Drug Therapy, | 2005 |
[Problems of the epidemiology, diagnosis, and treatment of caseous pneumonia].
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents; Antitubercular Agents; Diagnosis, Differential; Di | 2004 |
[Cervical spondylodiscitis: one pathogen may hide another].
Topics: Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Cervical Vertebrae; Cholecystitis; Disc | 2006 |
Isoniazid-induced crescentic glomerulonephritis in a child with a positive tuberculin skin test.
Topics: Adolescent; Antitubercular Agents; Disease Progression; Female; Glomerulonephritis; Humans; Isoniazi | 1998 |
Paradoxical worsening of tuberculosis after anti-TB therapy in a kidney transplant recipient.
Topics: Adult; Antitubercular Agents; Disease Progression; Drug Therapy, Combination; Ethambutol; Female; Hu | 2000 |
TB prevention in HIV clinics in New York City.
Topics: Adult; Antitubercular Agents; Disease Progression; Female; HIV Infections; Humans; Incidence; Isonia | 2001 |
New TB therapy works for HIV-positive patients.
Topics: Antitubercular Agents; Clinical Trials as Topic; Disease Progression; HIV Infections; Humans; Isonia | 1998 |
Would you know one if you met one?
Topics: Antitubercular Agents; Disease Progression; Humans; Isoniazid; Mycobacterium tuberculosis; Tuberculo | 2001 |